Pharmacokinetics Clinical Trial
Official title:
The Placebo Effect May Involve Modulating Drug Bioavailability
The total effect of a medication is the sum of its drug effect, placebo effect (meaning
response of placebo), and their interaction. Current interpretation of clinical trials (the
gold standard of evidence-based-medicine) assumes no interaction, and the mechanism(s)
underlying such interaction have not been fully explored. One possibility is that the
placebo effect may modulate drug bioavailability. Using caffeine as a model drug, we have
recently shown that the placebo effect of caffeine ingestion prolongs caffeine half life.
Due to the novelty of this finding and its important clinical practice and clinical research
implications, it needs to be confirmed in another set of subjects and extended to additional
drugs.
The results of the study are expected to further our understanding of the mechanism of
action of a widely used medical intervention, i.e., placebo. The results will be important
for both clinical practice and clinical research.
The total effect of a medication is the sum of its drug effect, placebo effect (meaning
response of placebo), and their interaction. Current interpretation of clinical trials (the
gold standard of evidence-based-medicine) assumes no interaction, and the mechanism(s)
underlying such interaction have not been fully explored. One possibility is that the
placebo effect may modulate drug bioavailability. Using caffeine as a model drug, we have
recently shown that the placebo effect of caffeine ingestion prolongs caffeine half life.
Due to the novelty of this finding and its important clinical practice and clinical research
implications, it needs to be confirmed in another set of subjects and extended to additional
drugs.
DESIGN: Balanced cross-over, single-dose, two-period, two-group deign comparing caffeine,
paracetamol, cephalexin, and ibuprofen described as such (overt) to the same medication
described as placebo (covert).
METHODS: 32, 50, 50, and 30 healthy adult volunteers will be enrolled in the caffeine (300
mg), paracetamol (500 mg), cephalexin (500 mg), and ibuprofen (400 mg) cross-over studies,
respectively. Volunteers will be partially deceived to the intervention assignment (i.e., in
the covert arm). Serum levels of each drug will be blindly determined by locally validated
HPLC assays. Plasma half life (primary outcome) as well as Cmax, Tmax, and AUC (secondary
outcomes) of each drug will be determined and analyzed by ANOVA.
;
Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04092725 -
Study to Evaluate the Effect of SCY-078 on the PK of Dabigatran in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT04181008 -
Pharmacokinetics of Amiloride Nasal Spray in Healthy Volunteers
|
Early Phase 1 | |
| Active, not recruiting |
NCT03258151 -
Association of Genetic Polymorphisms With Docetaxel-based Chemotherapy Toxicities in Chinese Solid Tumor Patients
|
||
| Completed |
NCT04406415 -
Oral Nafamostat in Healthy Volunteers
|
Phase 1 | |
| Not yet recruiting |
NCT05421312 -
Periarticular Penetration of Cefazolin and Clindamycin in Second Stage Revision Arthroplasty of the Hip
|
Phase 4 | |
| Completed |
NCT02534753 -
A Pharmacokinetics Study of Intravenous Ascorbic Acid
|
Phase 1 | |
| Completed |
NCT01682408 -
Assess Pharmacokinetics of Fostamatinib in Fed and Fasted State in Combination With Ranitidine to Assess Bioavailability
|
Phase 1 | |
| Completed |
NCT01976078 -
Development of Voriconazole Pharmacokinetics and Metabolism in Children and Adolescents
|
N/A | |
| Completed |
NCT01636024 -
To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of Inhaled AZD7594
|
Phase 1 | |
| Completed |
NCT01208155 -
Study in Healthy Males to Assess Bioavailability of 4 Different Fostamatinib Tablets
|
Phase 1 | |
| Completed |
NCT01415102 -
A First In Human Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Single Inhaled Doses Of PF-05212372.
|
Phase 1 | |
| Completed |
NCT01214941 -
Effect of Itraconazole and Ticlopidine on the Pharmacokinetics and Pharmacodynamics of Oral Tramadol
|
Phase 4 | |
| Completed |
NCT01260025 -
Tolerability and Pharmacokinetics of M2ES in the Treatment of Advanced Solid Tumor
|
Phase 1 | |
| Completed |
NCT00747721 -
Pharmacokinetics of Dexmedetomidine During Prolonged Infusion in ICU
|
Phase 1 | |
| Completed |
NCT01055964 -
a Comparative Pharmacokinetic Study of Two Oral Formulations of Tacrolimus in Renal Allograft Recipients
|
Phase 3 | |
| Completed |
NCT00746499 -
Pharmacokinetic Study of Raltegravir in Healthy Premenopausal Women.
|
Phase 1 | |
| Completed |
NCT00730145 -
A Single Dose Study Investigating The Elimination Of PD-0332334 In Patients Receiving Regular Hemodialysis
|
Phase 1 | |
| Completed |
NCT00984009 -
A Drug-Food Interaction Study Between Colchicine and Grapefruit Juice
|
Phase 1 | |
| Completed |
NCT01276119 -
The First Clinical Study to Test Safety, Blood Levels and Other Effects of CDP6038 in Healthy Males
|
Phase 1 | |
| Completed |
NCT00856570 -
A Clinical Study to Determine the Effect of YM178 on the Pharmacokinetics of Warfarin in Healthy Subjects
|
Phase 1 |